Navigation Links
GlaxoSmithKline’s Epilepsy Drug given the Green Signal by FD

The Food and Drug Administration. has given GlaxoSmithKline PLC's anti-seizure medicine to treat Primary Generalized Tonic-Clonic, or PGTC, the green signal.//

According to GlaxoSmithKline, the U.K. pharmaceutical company, the drug, Lamictal, has been approved to treat children age two and older, as well as adults.

PGTC seizures are said to be the most-serious and most-commonly occurring type of generalized seizures, seen in about 20% of patients with epilepsy.

Epilepsy is a recurrent, unprovoked seizure characterized by a change in sensation, awareness, or behavior which comes about by an electrical disturbance in the brain.

Lamictal has now received the fifth FDA approval. It been approved to treat partial and generalized seizures and as well as for use as maintenance therapy for adults with bipolar disorder.

The FDA's approval is said to have been based on a multicenter trial in pediatric and adult patients, which proved to be "highly effective" in reducing the frequency of generalized tonic-clonic seizures by 66%.


NLA
'"/>




Page: 1

Related medicine news :

1. GlaxoSmithKline’s Tykerb is to Be Started Earlier in Breast Cancer, Study Find
2. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
3. Researchers Scale to assess the Severity of Epilepsy in Kids
4. Epilepsy can be predicted
5. Epilepsy Drugs Can Enhance Risk of Birth Defects
6. Epilepsy Drug Helps Diabetic Nerve Damage
7. Epilepsy Drug May Relieve Chronic Headaches
8. More Complications Seen In Women With Epilepsy
9. Epilepsy Drugs Found To Lead To Bone Loss
10. Another Use For Epilepsy Drugs
11. Epilepsy Patients Could Benefit From Pacemakers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... ... management in hospitals, today announced it has completed a round of funding to ... LLC and its partners. Black Granite Capital is a growth equity firm focused ...
(Date:4/26/2017)... ... ... Journal of Oral Implantology – Tooth loss is not simply an ... complications with speech, eating, and overcompensation of mouth due to the deficiency. To combat ... number of tooth replacements increase, it is imperative to design an implant that will ...
(Date:4/26/2017)... ... April 26, 2017 , ... CareSet ... adoption of e-prescribing as measured in Part D Medicare data. The dataset, called ... pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") data ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, ... been honored by Enterprising Women magazine as one of its 2017 Enterprising Women ... business owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be a result ... has helped many women become pregnant upon treating their diagnosis. , ... outpatient evaluations. We can provide the necessary information to diagnose and treat ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
Breaking Medicine Technology: